According to reports from CNBC TV18, Gujarat Themis Biosyn Ltd (GTBL) has entered into a definitive agreement to acquire 100% equity shareholding of Japan-based MicroBiopharm Japan Co. Ltd (MBJ) through Themis Biosyn Japan Ltd, its wholly-owned subsidiary incorporated in Japan. The acquisition will be completed for a total consideration of JPY 21.5 billion, approximately ₹1,300 crore, subject to regulatory approvals and customary closing formalities. The transaction is being executed through Themis Biosyn Japan Limited, a wholly owned subsidiary of Gujarat Themis Biosyn Limited, and is expected to be EPS accretive. As per latest reports, this represents GTBL's largest acquisition to date, with the deal magnitude roughly equivalent to GTBL's total market capitalization from two years ago, signaling aggressive capital deployment.
As reported by CNBC TV18, the transaction will be funded through an optimal mix of debt and equity. The acquisition is subject to approval under Japan's Foreign Exchange and Foreign Trade Act (FEFTA) and other regulatory approvals. GTBL expects the acquisition to close in Q2 FY27, subject to satisfaction of customary closing conditions. The disclosure was signed by Dinesh S. Patel, Chairman & Director of Gujarat Themis Biosyn Limited on May 22, 2026. Latest reports indicate that the deal is expected to cause a re-rating of the GTBL stock as analysts factor in high-margin biopharma revenues, with the company's historically low debt levels suggesting this can be managed with optimal leverage.
According to CNBC TV18, MBJ reported estimated revenue of JPY 9.5 billion, approximately ₹570 crore, for FY26. The company's revenue from operations over the last three years stood at approximately ₹470 crore in FY23, ₹580 crore in FY24 and ₹560 crore in FY25. MBJ is engaged in research, development and manufacturing of APIs, intermediates and contract development and manufacturing (CDMO) services. The company's capabilities include microbial fermentation, biotechnology-based manufacturing, oncology APIs, plasmid DNA manufacturing, ADC conjugation and enzyme-based bioconversion platforms. Latest reports highlight that the global fermentation-derived API market is witnessing consolidation, with Microbiopharm Japan bringing specialized capabilities in complex microbial processes that are currently in high demand for next-generation biologics.
As reported by CNBC TV18, GTBL said the acquisition is part of its strategy to expand from a fermentation-led intermediates business into a technology-driven CDMO platform with capabilities across precision fermentation, biotechnology and next-generation drug manufacturing. The integration is expected to create a globally diversified platform, with proprietary pharmaceuticals and non-pharma products accounting for over 47% of MBJ's total revenue for FY26E. Additionally, approximately 40% of MBJ's revenue is derived from markets outside Japan. MBJ brings complementary capabilities including access to precision fermentation technologies, a P450 enzyme library, Plasmid DNA technology, and ADC Conjugation technology. The acquisition provides GTBL with advanced fermentation technology and an established market presence in Japan, complementing their existing API production, while entry into high-margin Japanese R&D and manufacturing pipelines offers significant growth potential.
According to CNBC TV18, shares of Gujarat Themis Biosyn Ltd ended at ₹364.50, up by ₹7.40, or 2.07%, on the BSE following the announcement. The transaction is not a related party transaction and is expected to transform GTBL into a globally integrated CDMO by leveraging MBJ's precision fermentation and biologics capabilities. Latest reports indicate that this acquisition represents a watershed moment for Gujarat Themis Biosyn, moving it from a steady-state API supplier to a growth-oriented biopharma leader. The deal is a clear signal of GTBL's intent to utilize its strong balance sheet for high-margin expansion, though retail investors should monitor the funding plan to check for potential equity dilution or increased debt-to-equity ratios. Key risks include currency volatility between JPY and INR affecting acquisition cost, operational integration risks in cross-border M&A, and potential dilution if the acquisition is funded via equity issuance.
